Financial Reports are Key to Consider: Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

On Thursday 30 May, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares price traded between $2.8000 and $3.0501 during the last trading session upbeat/downbeat with -8.17% at $2.8100. The shares recorded trading volume 1,103,900 shares as compared to its average volume of 1,138,715 shares. The company has 98.03M shares outstanding and market value of 275.475M.

Inovio Pharmaceuticals, Inc. (INO) recently stated financial results for the first quarter ended March 31, 2019. Inovio’s management will host a live conference call and webcast at 4:30 p.m. Eastern Time recently to discuss financial results and provide a general business update.

First Quarter 2019 Financial Results

Total revenue was $2.8M for the three months ended March 31, 2019, contrast to $1.5M for the same period in 2018. Total operating expenses were $31.4Mcontrast to $34.3M for the same period in 2018.

Inovio’s net loss for the quarter ended March 31, 2019 was $29.2M, or $0.30 per basic and diluted share, contrast to $32.4M, or $0.36 per basic and diluted share, for the quarter ended March 31, 2018.


The year over year raise in revenue under collaborative research and development arrangements was primarily Because of the milestone payment recognized in the first quarter 2019 from AstraZeneca.

Operating Expenses

Research and development (R&D) expenses for the three months ended March 31, 2019were $24.4M contrast to $24.6M for the same period in 2018. The decrease in R&D expenses was primarily related to a sub-license expense of $1.9M recorded in 2018 related to the ApolloBio collaboration, partially offset by an raise of $1.2Mrelated to Inovio’s VGX-3100 Phase 3 clinical trials, among other variances.

General and administrative (G&A) expenses were $7.0M for the three months ended March 31, 2019 versus $9.7M for the same period in 2018. The decrease in G&A expenses was primarily related to the foreign non-income taxes and advisory fees incurred in connection with the ApolloBio upfront payment Inovio received in 2018.

Capital Resources

As of March 31, 2019, cash and cash equivalents and short-term investments were $128.0M contrast to $81.2M as of December 31, 2018. As of March 31, 2019, the Company had 97.9M ordinary shares outstanding and 125.3M ordinary shares outstanding on a fully diluted basis, after giving effect to outstanding options, restricted stock units, convertible preferred stock and convertible notes.

In the first quarter 2019, the Company completed a private placement of $78.5Maggregate principal amount of 6.50% convertible senior notes due 2024. Net proceeds from the offering were about $75.7M.

The volatility in the previous week has experienced by 7.13% and observed of 5.22% in the previous month.44.30% ownership is held by institutional investors while insiders hold ownership of 4.00%.  The average true range of the stock is observed at 0.18 and the relative strength index of the stock is recorded at 24.81.


Leave a Reply

Your email address will not be published. Required fields are marked *